Cascino Thomas M, Sahay Sandeep, Moles Victor M, McLaughlin Vallerie V
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan.
Division of Pulmonary, Critical Care and Sleep Medicine, Houston Methodist Hospital, Houston, Texas.
J Heart Lung Transplant. 2025 Jan;44(1):1-10. doi: 10.1016/j.healun.2024.09.021. Epub 2024 Oct 5.
Despite increasing therapeutic options and evolving treatment strategies, including targeting 3 therapeutic pathways, in the management of pulmonary arterial hypertension (PAH), morbidity and mortality have remained unacceptably high. Sotatercept is a first-in-class, novel activin signaling inhibitor approved for treating PAH based on evolving efficacy and safety evidence. This state-of-the-art review summarizes the current understanding of the mechanism of action, the impact on outcomes that improve how patients feel, function, and survive, and the safety and adverse event profile to inform readers of this breakthrough novel therapy.
尽管在肺动脉高压（PAH）的管理方面，治疗选择不断增加，治疗策略也在不断演变，包括针对3条治疗途径，但发病率和死亡率仍然高得令人无法接受。索他洛尔是一种一流的新型激活素信号抑制剂，基于不断发展的疗效和安全性证据被批准用于治疗PAH。这篇前沿综述总结了目前对其作用机制的理解、对改善患者感受、功能和生存的结局的影响，以及安全性和不良事件概况，以便让读者了解这一突破性的新型疗法。
